SCHEDULE: Morgan Stanley Boosts Stake in Chemomab to 8.4%

Morgan Stanley and its subsidiary have disclosed an 8.4% beneficial ownership stake in Chemomab Therapeutics Ltd. as of June 30, 2025.

Summary

• Morgan Stanley and its wholly-owned subsidiary, Morgan Stanley & Co. LLC, have filed a Schedule 13G.
• The filing reports beneficial ownership of Ordinary Shares / American Depositary Shares of Chemomab Therapeutics Ltd.
• As of June 30, 2025, Morgan Stanley beneficially owns an aggregate of 32,282,680 shares, representing 8.4% of the class.
• Morgan Stanley & Co. LLC beneficially owns 28,786,680 shares, representing 7.5% of the class.
• Both entities report shared voting and shared dispositive power over their respective holdings.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a large, reputable financial institution has taken a significant stake in the company, which can be interpreted as a vote of confidence. However, the filing itself is purely factual and does not contain performance data.

Positives

• A major financial institution like Morgan Stanley taking a significant stake (8.4%) can signal confidence in Chemomab Therapeutics Ltd.'s future prospects.
• The acquisition of shares in the ordinary course of business suggests a long-term investment perspective rather than an activist stance.

Risks

• The filing itself does not detail specific business risks of Chemomab Therapeutics Ltd.; it is a disclosure of beneficial ownership.

Future Outlook

The filing is a disclosure of past beneficial ownership and does not contain forward-looking statements or guidance regarding Chemomab Therapeutics Ltd.'s future performance or Morgan Stanley's future investment intentions beyond the statement that shares are held in the ordinary course of business.

Industry Context

This filing indicates a significant institutional investment in a biotechnology company, which is common in the sector as large funds seek exposure to innovative drug development and potential growth. The specific impact on broader industry trends is limited to the signal of institutional interest in this particular company.

Stakeholder Impact

• Shareholders may view Morgan Stanley's significant stake as a positive signal, potentially increasing investor confidence and attracting further institutional interest.
• The company's management might see this as validation of their strategy and a stable long-term investor.

Key Dates

Keywords

Chemomab Therapeutics, Morgan Stanley, Schedule 13G, Beneficial Ownership, Institutional Investment, Biotechnology, Pharmaceuticals, CMAB, SEC Filing